leisure time -WSS

leisure time

author：knowledge 2025-09-29 01:36:49 - browse：8

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

J&J to buy cancer drug developer Ambrx Biopharma

Abridge raises $150m as clinical notes automation market heats up

New weight loss drugs work. But how can they best be used?

UCB departs biotech trade group BIO

Abridge raises $150m as clinical notes automation market heats up

Wikipedia

leisure time

leisure time

In Memoriam: Notable people who died in 2023

White House finalizes ITC's import ban of latest Apple Watches

Continuity nursing helped my family in our darkest PICU moments

Abridge raises $150m as clinical notes automation market heats up

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

After affirmative action ruling, medical educators look to 'holistic review'

Obamacare plans could cover weight loss drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

hotspot

3 medical device trends to watch in 2024

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Hospitals are piloting generative AI tools as regulators play catch

AdventHealth escalates lawsuit against insurance vendor Multiplan

WATCH: Why do our ears pop?

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

hotspot

knowledge

leisure time

leisure time